文献速递神经肿瘤

TSPO-PET与扩散加权MRI用于浸润性人胶质瘤小鼠模型成像

TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.
PubMed 文献 · Neuro Oncol · 2019-01-01

研究在人浸润性胶质瘤模型中评估[18F]DPA-714 TSPO-PET、[18F]FET PET、非高斯扩散MRI(表观扩散系数、峰度)及复合扩散指标S-index检测肿瘤浸润的能力。结果显示[18F]DPA-714摄取比在胶质瘤细胞植入7周后开始升高,TSPO-PET较[18F]FET提前2周显示对侧半球浸润,峰度在5周时较标准T2加权MRI更敏感。作者认为先进PET与MRI方法在早期显示胶质瘤生长和浸润方面可能优于标准成像。

要点

  • 胶质瘤细胞植入7周后肿瘤对侧[18F]DPA-714摄取比升高至1.49 ± 0.11。
  • TSPO-PET较[18F]FET提前2周显示胶质瘤向对侧半球浸润。
  • 5周时峰度较标准T2加权MRI更敏感地检出荷瘤与对侧半球的差异。

核心结论

  • 作者认为先进PET与MRI方法(如[18F]DPA-714和DWI)在早期显示胶质瘤生长和浸润方面可能优于标准成像方法。

研究设计与样本

  • 在人浸润性胶质瘤模型中使用多模态成像,评估靶向18 kDa转位蛋白(TSPO)的放射性示踪剂[18F]DPA-714、[18F]FET PET、非高斯扩散MRI(表观扩散系数、峰度)及复合扩散指标S-index。
  • 体内成像结果经放射自显影和免疫荧光确认。

主要发现

  • 胶质瘤细胞植入7周后开始出现肿瘤对侧[18F]DPA-714摄取比升高(1.49 ± 0.11)。
  • TSPO-PET较临床相关胶质瘤生物活性标志物[18F]FET提前2周显示胶质瘤向对侧半球浸润。
  • 扩散加权成像尤其是峰度在5周时较标准T2加权MRI更敏感地检出荷瘤半球与对侧半球的差异。
  • 免疫荧光数据反映体内成像所见,肿瘤与间质TSPO标记提示TSPO主要由肿瘤细胞表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most devastating brain tumor. Despite the use of multimodal treatments, most patients relapse, often due to the highly invasive nature of gliomas. However, the detection of glioma infiltration remains challenging. The aim of this study was to assess advanced PET and MRI techniques for visualizing biological activity and infiltration of the tumor. METHODS: Using multimodality imaging, we investigated [18F]DPA-714, a radiotracer targeting the 18 kDa translocator protein (TSPO), [18F]FET PET, non-Gaussian diffusion MRI (apparent diffusion coefficient, kurtosis), and the S-index, a composite diffusion metric, to detect tumor infiltration in a human invasive glioma model. In vivo imaging findings were confirmed by autoradiography and immunofluorescence. RESULTS: Increased tumor-to-contralateral [18F]DPA-714 uptake ratios (1.49 ± 0.11) were found starting 7 weeks after glioma cell implantation. TSPO-PET allowed visualization of glioma infiltration into the contralateral hemisphere 2 weeks earlier compared with the clinically relevant biomarker for biological glioma activity [18F]FET. Diffusion-weighted imaging (DWI), in particular kurtosis, was more sensitive than standard T2-weighted MRI to detect differences between the glioma-bearing and the contralateral hemisphere at 5 weeks. Immunofluorescence data reflect in vivo findings. Interestingly, labeling for tumoral and stromal TSPO indicates a predominant expression of TSPO by tumor cells. CONCLUSION: These results suggest that advanced PET and MRI methods, such as [18F]DPA-714 and DWI, may be superior to standard imaging methods to visualize glioma growth and infiltration at an early stage.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Pigeon H, Pérès EA, Truillet C, et al. TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma. Neuro Oncol. 2019. PMID: 30721979. doi:10.1093/neuonc/noz029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。